Omeros (NASDAQ:OMER) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER - Free Report) in a report released on Friday morning,Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company's stock.

A number of other equities research analysts have also issued reports on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. StockNews.com downgraded shares of Omeros from a "hold" rating to a "sell" rating in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $22.50.

Omeros Trading Down 2.2 %

OMER traded down $0.15 during mid-day trading on Friday, hitting $6.72. 139,389 shares of the stock were exchanged, compared to its average volume of 571,053. The company has a market cap of $390.19 million, a PE ratio of -2.91 and a beta of 2.35. The firm's fifty day moving average is $8.12 and its two-hundred day moving average is $7.79. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.08. During the same quarter last year, the business earned ($0.15) EPS. As a group, research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. Truvestments Capital LLC grew its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Omeros during the fourth quarter worth about $46,000. Picton Mahoney Asset Management lifted its holdings in shares of Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 4,404 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 7,388 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.